Document is current
Any future updates will be listed below
-
Authors
Shin, Baehyun https://orcid.org/0000-0001-9892-5279
Wang, Monica
Yim, John
Kwon, Elisa
Magdesian, Margaret H.
Sayegh, Camil E.
Ekert, Jason E.
Vadysirisack, Douangsone D.
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 21 November 2025
First Online: 12 December 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Sera from myasthenia gravis patients were collected by BIOIVT with informed consent, adhering to the Department of Health and Human Services regulations (45 CFR §46.116 and §46.117) and Good Clinical Practice (ICH E6 R2). The protocols and consent forms used for the collection of human biological samples (HBS) were reviewed and approved by the ethics committee, specifically WCG IRB (IRB00000533). No animal subjects were involved in this study.
: Not applicable.
: BS, MW and JEE are current UCB employees and have equity ownership. JY and EK are former employees at UCB and have no disclosures. MHM is the CEO and founder and a shareholder of Ananda Devices Inc. The NeuroMuscle™ platform is protected under the patent US 18/939,478, owned by Ananda Devices Inc. CES and DDV are former employees at UCB and have equity ownership. The study was funded by UCB.
